pembrolizumab

Overview

Pembrolizumab (Keytruda, known in development as MK-3475 and lambrolizumab) is a humanized IgG4 monoclonal antibody that blocks the programmed cell death 1 (PD-1) checkpoint receptor. PD-1 is expressed on activated cytotoxic T cells, regulatory T cells and natural killer cells, where it restrains immune activation; binding it prevents engagement by PD-L1 and PD-L2, which tumor cells and cells of the tumor microenvironment exploit to suppress local T-cell responses. The IgG4 backbone is deliberate — it is engineered with a stabilized hinge to prevent Fab-arm exchange and, unlike IgG1, recruits little effector function, since an antibody that killed the PD-1-bearing T cells it binds would defeat its own purpose. The result is restoration of T-cell-mediated antitumor immunity rather than direct cytotoxicity, which distinguishes it from chemotherapy: it acts on the host immune system, not on the tumor. It belongs to the checkpoint inhibitor class alongside anti-PD-1 antibodies such as nivolumab and cemiplimab, anti-PD-L1 agents including avelumab, and CTLA-4 inhibitors such as ipilimumab.

It is among the most broadly indicated oncology agents, used in melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, renal cell carcinoma, hepatocellular carcinoma, gastric and gastroesophageal junction Cancers, cervical cancer and triple-negative breast cancer, and — in a departure from organ-based oncology — in any solid tumor with mismatch repair deficiency, high microsatellite instability or high tumor mutational burden, the first approvals granted on a molecular feature alone. PD-L1 expression, scored as combined positive score or tumor proportion score, guides selection where it is required, though the threshold and even the necessity vary by indication. Dosing is fixed rather than weight-based, 200 mg every three weeks or 400 mg every six weeks, in both advanced disease and increasingly as adjuvant therapy after resection.

Combinations define much of its current use: with platinum chemotherapy (cisplatin, carboplatin) and with nucleoside analogues such as gemcitabine, with the antibody-drug conjugate enfortumab vedotin in urothelial carcinoma, and with targeted agents such as lenvatinib and the HIF-2α inhibitor belzutifan. Because the mechanism lifts a physiological restraint, the characteristic toxicities are immune-related adverse events across skin, endocrine organs, gut, liver, lung, muscle, heart and nervous system; they can appear months into treatment or after it stops, are treated by immunosuppression rather than by dose reduction, and endocrine damage is frequently permanent.

Recent Publications Summary (3 months)

Recent publications on pembrolizumab focused heavily on real-world effectiveness, biomarker refinement, safety, and combination strategies across several tumor types. In metastatic non-small cell lung cancer, studies examined first-line pembrolizumab monotherapy in PD-L1-high disease, including comparisons of trial-derived and Australian real-world outcomes for cost-effectiveness, as well as routine-practice effectiveness and safety in patients with PD-L1 expression ≥50% and no EGFR or ALK alterations 42507245Jul42285782Jun. Additional work evaluated how pembrolizumab dosing changes from 200 mg every 3 weeks to 400 mg every 6 weeks may affect pharmacokinetics and immune-related adverse events, and whether concomitant proton pump inhibitor use influences efficacy or toxicity during pembrolizumab monotherapy 42373128Jun42373280Jun.

Several publications addressed pembrolizumab-based combinations in genitourinary Cancers. In metastatic urothelial carcinoma, enfortumab vedotin plus pembrolizumab was studied in a phase 3 perioperative trial for cisplatin-eligible muscle-invasive bladder cancer and in real-world cohorts assessing effectiveness and safety in metastatic or locally advanced disease 42485627Jul42437411Jul. Other studies compared pembrolizumab-containing strategies with alternative standards of care, including a real-world comparison of avelumab maintenance versus enfortumab vedotin plus pembrolizumab and a retrospective analysis of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib in metastatic renal cell carcinoma 42373274Jun42204034May. In renal-cell carcinoma, pembrolizumab also appeared in adjuvant and investigational settings, including real-world implementation after surgery and a proposed adjuvant pembrolizumab plus belzutifan approach 42379743Jun42384869Jul.

In other solid tumors, pembrolizumab was evaluated in recurrent or metastatic head and neck squamous cell carcinoma, where lenvatinib plus pembrolizumab was tested against standard of care in a randomized phase 2 study, and quality-of-life outcomes were assessed in real-world practice 42241967Jun42203315May. In triple-negative breast cancer, publications examined pembrolizumab added to neoadjuvant chemotherapy, including predictors of pathologic complete response and the contribution of germline BRCA status to efficacy and toxicity 42329463Jun42207343May. Pembrolizumab was also studied in advanced anal cancer, metastatic metaplastic breast carcinoma, and rare tumors, including a prospective phase 2 biomarker study showing objective responses and clinical benefit across histologies 42109075May42142352May42167248May.

Mechanistic and safety-focused reports highlighted pembrolizumab-associated immune effects and biomarker development. A real-world pharmacovigilance analysis in hepatocellular carcinoma identified adverse-event signals for pembrolizumab plus lenvatinib, including immune-mediated hepatitis and hepatic encephalopathy 42461453Jul. Case-based and translational studies described severe pembrolizumab-induced eczematous dermatitis managed with methotrexate, a complete response in mismatch repair-deficient prostate cancer, and artificial intelligence-guided tumor microenvironment analysis as a predictor of response in rare tumors 42425603Jul42361800Jun42342409Jun. Additional work suggested that broader gene representation by whole-exome sequencing may improve tumor mutational burden assessment for selecting patients for pembrolizumab, and that immune-cell spatial features such as regulatory T cell proximity to CD3 T cells may help predict benefit in pembrolizumab-based therapy 42113041May42126144May.

What Changes, What Holds

1. Real-world PD-L1-high lung cancer practice reproduces trial-grade benefit, and the every-6-week dose is not yet proven interchangeable
REINFORCES Routine-practice effectiveness in PD-L1 ≥50% EGFR/ALK-wild-type disease confirms the biomarker-guided selection strategy the baseline already treats as settled 42285782Jun. The open question is narrower and more practical: the 400 mg q6w schedule the Overview lists alongside 200 mg q3w as equivalent is being interrogated for divergent pharmacokinetics and immune-related toxicity, and concomitant acid suppression for efficacy modulation 42373128Jun. Neither is resolved; if the q6w comparison turned out negative it would cut against a dosing claim the baseline states flatly.

2. Head-to-head comparisons put pembrolizumab regimens in contests they can lose
NEW DIRECTION Direct comparison against non-pembrolizumab standards — avelumab maintenance, nivolumab plus cabozantinib — moves the drug from a catalogue of indications, which is all the Overview offers, into a competitive ranking where a regimen can be the inferior choice 42373274Jun42204034May. Retrospective and real-world designs make these rankings provisional, not practice-defining. Perioperative enfortumab vedotin use and adjuvant belzutifan pairing extend established combinations earlier in the disease course rather than changing their logic.

3. Responses in rare and uncharacterized histologies loosen the tie between indication lists and expected benefit
NEW DIRECTION Prospective biomarker-selected activity across mixed rare histologies suggests eligibility is better framed by tumor biology than by the organ-based indication catalogue the Overview enumerates 42167248May. Germline BRCA status emerging as a modifier of neoadjuvant efficacy and toxicity in triple-negative breast cancer adds a host-genetic axis the baseline's PD-L1/MSI/TMB framework does not contain 42207343May. Both remain single-study observations awaiting replication before they should guide selection.

4. Spatial immune architecture and exome-wide mutational burden outperform the biomarkers currently used to select patients
METHOD Measurement, not mechanism, is what changes here: regulatory T cell proximity to CD3 T cells as a predictive spatial feature and whole-exome-based TMB recalibration both target the selection step the Overview describes with combined positive score, tumor proportion score, and panel-derived burden 42126144May42113041May. Adopting them would revise thresholds, not the checkpoint account. The hepatitis and encephalopathy signals with lenvatinib sit within the immune-related toxicity profile the baseline already names.

Overview update candidates: none — the comparative-effectiveness losses and spatial/exome biomarkers are the strongest candidates but rest on retrospective or single-study evidence.